Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Pembrolizumab (Keytruda) for Melanoma Adjuvant Treatment
(Pending Submission as of November 9, 2018)

Brigatinib (Alunbrig) for Non-Small Cell Lung Cancer
(Pending Submission as of November 7, 2018)

Abemaciclib (Brand Name: TBD) for Metastatic Breast Cancer
(Pending Submission as of November 5, 2018)

Ixazomib (Ninlaro) for Multiple Myeloma (2nd-beyond)
(Pending Submission as of November 2, 2018)

Osimertinib (Tagrisso) for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (first line)  
(Open for Feedback on Recommendation until November 15, 2018)

Lenvatinib (Lenvima) for Advanced Renal Cell Carcinoma
(Open for Feedback on Recommendation until November 15, 2018)

Obinutuzumab (Gazyva) for Follicular Lymphoma (previously untreated)
(Final Recommendation Issued as of November 1, 2018)

Apalutamide (Erleada) for Castrate Resistant Prostate Cancer 
(Final Recommendation Issued as of November 1, 2018)

Nivolumab (Opdivo) in combination with Ipilimumab (Yervoy) for Renal Cell Carcinoma
(Final Recommendation Issued as of November 1, 2018)

Crizotinib (Xalkori) for ROS1-Positive Non-Small Cell Lung Cancer
(Open for Input on Submission until November 13, 2018)

Venetoclax (Venclexta) in combo Rituximab for Chronic Lymphocytic Leukemia
(Open for Input on Submission until November 7, 2018)

Find a Drug Review